Citations

Showing 10 of 108152 citations.

RasGRP1 is a potential biomarker for stratifying anti-EGFR therapy response in colorectal cancer
Gbenedio, Oghenekevwe M. , Bonnans, Caroline , Grün, Delphine , Wang, Chih‐Yang , Hatch, Ace J. , Mahoney, Michelle R., Matli, Mary, Miao, Yi , García, K. Christopher , Delorenzi, Mauro , Warren, Robert S. , Roose, Jeroen P. , Depeille, Philippe , Nixon, Andrew B. , Barras, David , Tejpar, Sabine , Venook, Alan P.

Mayo Clinic

JCI Insight | June 25, 2019 | Volume: 4 | Issue: 15 | Pages: No page available

10.1172/jci.insight.127552 | PMID 31237864 Get It

Colorectal cancer (CRC) is the third most frequent neoplastic disorder and is a main cause of tumor-related mortality, as many patients progress to stage IV metastatic CRC. Standard care consists of combination chemotherapy (FOLFIRI or FOLFOX). Patients with WT KRAS typing are eligible to receive anti-EGFR therapy combined with chemotherapy. Unfortunately, predicting efficacy of CRC anti-EGFR therapy has remained challenging. Here we uncovered that the EGFR pathway component RasGRP1 acts as a CRC tumor suppressor in the context of aberrant Wnt signaling. We found that RasGRP1 suppresses EGF-driven proliferation of colonic epithelial organoids. Having established that RasGRP1 dosage levels impact biology, we next focused on CRC patients. Mining 5 different data platforms, we establish that RasGRP1 expression levels decrease with CRC progression and predict poor clinical outcome of patients. Last, deletion of 1 or 2 Rasgrp1 alleles made CRC spheroids more susceptible to EGFR inhibition. Retrospective analysis of the CALGB 80203 clinical trial showed that addition of anti-EGFR therapy to chemotherapy significantly improved outcome for CRC patients when tumors expressed low levels of RasGRP1 suppressor. In sum, our data support RasGRP1 as a biomarker in the EGFR pathway that has potential relevance to anti-EGFR therapy for CRC patients.
Natural History of Adrenal Incidentalomas With and Without Mild Autonomous Cortisol Excess
Elhassan, Yasir , Alahdab, Fares , Prete, Alessandro , Delivanis, Danae A. , Khanna, Aakanksha, Murad, M. Hassan , Arlt, Wiebke , Murad, Mohammad H, Murad, M Hassan , Arlt, Wiebke , Prete, Alessandro , Prokop, Larry J. , O'Reilly, Michael W , Bancos, Irina , Elhassan, Yasir S , Alahdab, Fares

Mayo Clinic

Annals of Internal Medicine | June 25, 2019 | Volume: 171 | Issue: 2 | Pages: 107-116

10.7326/m18-3630 | PMID 31234202 Get It

The Differential Impact of Social Media Use on Middle and High School Students: A Retrospective Study
Shafi, Reem M.A. , Nakonezny, Paul A. , Romanowicz, Magdalena , Nandakumar, Aiswarya Laks, Suarez, Laura , Nandakumar, Aiswarya L, Croarkin, Paul E.

Mayo Clinic

Journal of Child and Adolescent Psychopharmacology | June 25, 2019 | Volume: 29 | Issue: 10 | Pages: 746-752

10.1089/cap.2019.0071 | PMID 31233343 Get It

Background: Social media use is now a central aspect of adolescent life and development. Little is known about the clinical implications of social media use in children and adolescents presenting in acute crisis for psychiatric admission. This study sought to compare the potential effects of social media use among middle and high school students on outcomes of psychiatric morbidity. It was hypothesized that among social media users, high school students would have greater psychiatric morbidity compared with middle school students. Methods: The research team extracted clinical and demographic data from adolescents (aged 12–17 years) presenting for acute psychiatric admission who also had documented social media use ( N = 56). Educational status, middle school ( n = 21) versus high school ( n = 35), was examined as an independent variable. Psychotropic medication use, self-injurious behavior, suicide risk, and suicidal ideation were examined as dependent variables in logistic regression models. Results: High school students using social media had significantly greater predicted odds of psychotropic medication use and self-injurious behavior compared with students in middle school who used social media. High school students using social media had greater, although not statistically significant, predicted odds of suicide risk and suicidal ideation compared with middle school students using social media. Conclusions: Social media use is likely an important factor to consider in psychiatric evaluations. The present findings suggest that social media use in high school students is associated with greater psychiatric morbidity compared with middle school students. Further research could illuminate the developmental lines of social media use and age-specific risks.
Lung Function - Ultraendurance Marathon
Wheatley, Courtney M. , Chabridon, Loïc, Gavet, Alice , Ziegler, Briana, Schwartz, Jesse C., Robach, Paul , Johnson, Bruce D. , Fermoyle, Caitlin C. , Stewart, Glenn M. , Taylor, Bryan J.

Mayo Clinic

Medicine & Science in Sports & Exercise | June 25, 2019 | Volume: 51 | Issue: 6S | Pages: 628-629

10.1249/01.mss.0000562381.31349.f8 Get It

Eptinezumab for prevention of chronic migraine: A randomized phase 2b clinical trial
Silberstein, Stephen D., Goadsby, Peter J. , Biondi, David M., Hirman, Joe, Cady, Roger , Smith, Jeff , Goadsby, Peter J , Dodick, David W. , Lipton, Richard B.

Mayo Clinic

Cephalalgia | June 25, 2019 | Volume: 39 | Issue: 9 | Pages: 1075-1085

10.1177/0333102419858355 | PMID 31234642 Get It

Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. We evaluated eptinezumab, an intravenous (IV) anti-calcitonin gene-related peptide monoclonal antibody, for the prevention of chronic migraine. Objective To determine the safety, tolerability, and effectiveness of four dose levels of eptinezumab and to inform the phase 3 development program. Methods This was a phase 2b, parallel-group, double-blind, randomized, placebo-controlled, dose-ranging clinical trial. Men and women (N = 616) aged 18–55 years were included if they had a diagnosis of chronic migraine, with onset at age ≤35 years and history of chronic migraine ≥1 year. During the 28-day screening period, patients must have had ≥15 headache days, including ≥8 migraine days, with ≥5 migraine attacks as recorded in the electronic diary. Patients were assigned in a 1:1:1:1:1 ratio to eptinezumab 300, 100, 30, 10 mg or placebo, administered as a single IV infusion. The primary endpoint was the percentage of patients with a ≥75% decrease in monthly migraine days over weeks 1–12 compared with the 28-day screening period. Results The ≥75% migraine responder rates over weeks 1–12 for eptinezumab 300, 100, 30, and 10 mg were 33.3%, 31.4%, 28.2%, and 26.8%, respectively, versus 20.7% for placebo ( p = 0.033, 0.072, 0.201, 0.294 vs. placebo). Secondary efficacy endpoints (e.g. ≥50% responder rate, change from baseline in frequency of migraine/headache days, and percentage of severe migraines) had results favoring the three higher eptinezumab doses versus placebo. Eptinezumab was well tolerated and adverse event rates were similar to placebo. Conclusions The results of this trial demonstrate that eptinezumab appears effective and well-tolerated for the preventive treatment of chronic migraine and justifies the conduct of pivotal phase 3 trials for migraine prevention. Trial Registration ClinicalTrials.gov identifier: NCT02275117.
Myosin IIA suppresses glioblastoma development in a mechanically sensitive manner
Picariello, Hannah S., Kenchappa, Rajappa S., Crish, James F. , Dovas, Athanassios, Pogoda, Katarzyna , McMahon, Mariah, Bell, Emily , Chandrasekharan, Unnikrishnan M. , Luu, Amanda, West, Rita, Canoll, Peter , Odde, David J. , Janmey, Paul A. , Egelhoff, Thomas, Rosenfeld, Steven S. , McMahon, Mariah , Odde, David J , Rai, Vandana, Luu, Amanda, Lammerding, Jan

Mayo Clinic

Proceedings of the National Academy of Sciences | June 25, 2019 | Volume: 116 | Issue: 31 | Pages: 15550-15559

10.1073/pnas.1902847116 | PMID 31235578 Get It

Significance Glioblastoma, the most common and lethal of primary brain tumors, can diffusely infiltrate brain. Because the components of the cytoskeleton that drive tumor invasion are nonredundant, they have been attractive targets for blocking glioblastoma dispersion. However, we find that while targeting one of these—the molecular motor myosin IIA—effectively blocks glioblastoma invasion, it enhances tumor proliferation and lethality. In this study, we have found that myosin IIA functions as a tumor suppressor by reducing signaling of two oncogenes—ERK1/2 and NF-κB—in a manner regulated by the mechanics of the tumor and surrounding brain. Our results also argue that effective treatment of glioblastoma will require inhibiting targets that drive both invasion and proliferation.
Spontaneous coronary artery dissection: etiology and recurrence
Tan, Nicholas Y. , Tweet, Marysia S.

Mayo Clinic

Expert Review of Cardiovascular Therapy | June 24, 2019 | Volume: 17 | Issue: 7 | Pages: 497-510

10.1080/14779072.2019.1635011 | PMID 31232618 Get It

NKG2D–DAP10 signaling recruits EVL to the cytotoxic synapse to generate F-actin and promote NK cell cytotoxicity
Wilton, Katelynn M. , Overlee, Brittany L., Billadeau, Daniel D.

Mayo Clinic

Journal of Cell Science | June 24, 2019 | Volume: 133 | Issue: 5 | Pages: No page available

10.1242/jcs.230508 | PMID 31235500 Get It

ABSTRACT Natural killer (NK) cells eliminate abnormal cells through the release of cytolytic granule contents. In this process, NK cells must adhere to target cells through integrin-mediated adhesion, which is highly dependent on the generation of F-actin. Ena/VASP-like (EVL) is an actin regulatory protein previously shown to regulate integrin-mediated adhesion in other cell types, but its role in NK cell biology is not known. Herein, we show that EVL is recruited to the NK cell cytotoxic synapse and is required for NK cell cytotoxicity. Significantly, EVL is involved in the generation of F-actin at the cytotoxic synapse, antibody-stimulated spreading, and NK cell-target cell adhesion. EVL interacts with WASP (also known as WAS) and VASP and is required for localization of both proteins to the synapse. Recruitment of EVL to points of cellular activation occurs through the receptor NKG2D–DAP10 (also known as KLRK1 and HCST, respectively) via a binding site previously implicated in VAV1 and Grb2 recruitment. Taken together, this study implicates DAP10-mediated Grb2 and VAV1 signaling in the recruitment of an EVL-containing actin regulatory complex to the cytotoxic synapse where it can promote F-actin nucleation leading to NK cell-mediated killing.
Standardized classification and reporting of glomerulonephritis
Sethi, Sanjeev , Fervenza, Fernando C.

Mayo Clinic

Nephrology (Saint-Petersburg) | June 24, 2019 | Volume: 23 | Issue: 4 | Pages: 27-35

10.24884/1561-6274-2019-23-4-27-35 Get It

Incidence and outcomes of systemic infections in patients with leadless pacemakers: Data from the Micra IDE study
El‐Chami, Mikhael F. , Soejima, Kyoko , Piccini, Jonathan P. , Reynolds, Dwight, Ritter, Philippe , Okabe, Toshimasa , Friedman, Paul A. , Cha, Yong‐Mei , Stromberg, Kurt , Holbrook, Reece , Fagan, Dedra H. , Roberts, Paul R. , El-Chami, Mikhael F , Stromberg, Kurt

Mayo Clinic

Pacing and Clinical Electrophysiology | June 24, 2019 | Volume: 42 | Issue: 8 | Pages: 1105-1110

10.1111/pace.13752 | PMID 31232461 Get It

AbstractBackgroundThe Micra clinical trials have enrolled more than 2500 patients without any reported device‐related infections that required removal during follow‐up. Leadless pacemakers might be more resistant to bacterial seeding due to smaller surface area and a greater tendency for encapsulation.ObjectiveTo analyze the incidence and outcomes of serious infectious events (SIEs: bacteremia or endocarditis) that developed during follow‐up in patients with history of Micra leadless pacemaker implantation.MethodsSIE and outcomes were characterized based upon adverse event reports. Among 720 patients implanted with Micra in the investigational device exemption trial, we identified 16 patients who had documented 21 SIEs during follow‐up.ResultsAmong patients with SIEs, mean age was 71.9 ± 11.7 years. SIEs occurred at a mean 4.8 ± 4.5 months after implant and patients were followed for 13.1 ± 9.1 months after documentation of SIE. All events were adjudicated as unrelated to the Micra device or procedure. Bacteremia was documented to be related to a gram‐positive organism in 13 events (seven Staphylococcus, three Streptococcus, two Enterococcus, and one uncharacterized gram‐positive bacteria), and gram‐negative organisms in three events. In five events, the type of organism was not characterized (two patients with endocarditis). No persistent cases of bacteremia after antibiotic cessation were seen over the duration of follow‐upConclusionIn this small series of Micra patients who developed SIEs postimplant, the occurrence of bacteremia and/or endocarditis did not appear to lead to persistent bacteremia off antibiotics; most events resolved with antibiotic treatment.